SCHEMBL3004577

SCHEMBL3004577

CCOc1ccc(Cc2csc(N3CCN(S(=O)(=O)c4ccc(Cl)c(Cl)c4)CC3)n2)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 1/20 0.48
KDM4E B2RXH2 2/20 0.46
TSHR P16473 2/20 0.46
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46
THRB P10828 1/20 0.45
LMNA P02545 2/20 0.45
POLB P06746 1/20 0.45
L3MBTL1 Q9Y468 2/20 0.45
GAA P10253 2/20 0.43
NPSR1 Q6W5P4 1/20 0.43
ALDH1A1 P00352 3/20 0.43
SMN1; SMN2 Q16637 3/20 0.43
HPGD P15428 1/20 0.43
HSD17B10 Q99714 1/20 0.43
YAP1 P46937 1/20 0.42
TEAD4 Q15561 1/20 0.42
TEAD2 Q15562 1/20 0.42
APOBEC3A P31941 1/20 0.42
CTDSP1 Q9GZU7 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3001249 0.92 TDP1 (0.48) TDP1KDM4ETSHRMEN1KMT2A
SCHEMBL3016522 0.91 POLB (0.48) KDM4ETSHRMEN1KMT2ATHRB
SCHEMBL3009005 0.91 TDP1 (0.60) TDP1TSHRMEN1KMT2ALMNA
SCHEMBL3011226 0.90 TDP1 (0.49) TDP1KDM4ETSHRMEN1KMT2A
SCHEMBL3014640 0.90 VCAM1 (0.48) TDP1KDM4ETSHRMEN1KMT2A
SCHEMBL3014321 0.90 THRB (0.57) MEN1KMT2ATHRBLMNAL3MBTL1
SCHEMBL3001708 0.89 TDP1 (0.47) TDP1KDM4ETSHRMEN1KMT2A
SCHEMBL3009148 0.88 THRB (0.47) MEN1KMT2ATHRBLMNAPOLB
SCHEMBL3014207 0.88 LMNA (0.54) TDP1MEN1KMT2ALMNAPOLB
SCHEMBL3017901 0.88 THRB (0.47) KDM4EMEN1KMT2ATHRBL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA TDP1 86/4885KDM4E 4398/4885TSHR 3320/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.